ABCB7 and acute myeloid leukemia: As we identified SF3B1-mutated AML as highly responsive to S767 (Fig. 1, H and I) and optimized UM4118 activity on ABCB7 depleted cells (Fig. 4A), we tested UM4118 potency in a panel of 14 primary AMLs carrying or not SF3B1 mutations.